14-3-3 proteins in the nervous system

Nature Reviews Neuroscience

Volumn 4, Issue 9, 2003, Pages 752-762

  Berg, Daniela ^a,b   Holzmann, Carsten ^c   Riess, Olaf ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c UNIVERSITY OF ROSTOCK   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ISOPROTEIN; PROTEIN 14 3 3; TYROSINE 3 MONOOXYGENASE; ION CHANNEL;

ANIMAL; APOPTOSIS; CHEMISTRY; GENETICS; HUMAN; METABOLISM; NERVOUS SYSTEM; PATHOLOGY; PHYSIOLOGY; REVIEW; CELL CYCLE; CEREBROSPINAL FLUID; NERVE DEGENERATION; NEUROLOGIC DISEASE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION;

14-3-3 PROTEINS; ANIMALS; APOPTOSIS; HUMANS; NERVOUS SYSTEM; PROTEIN ISOFORMS; TYROSINE 3-MONOOXYGENASE;

EID: 0141722623     PISSN: 1471003X     EISSN: 14710048     Source Type: Journal    
DOI: 10.1038/nrn1197     Document Type: Article

References (157)

1. Yaffe, M. B. How do 14-3-3 proteins work? — Gatekeeper phosphorylation and the molecular anvil hypothesis. FEBS Lett. 513, 53-57 (2002).
2. van Hemert, M. J., Steensma, H. Y. & van Heusden, G. P. 14-3-3 proteins: key regulators of cell division, signalling and apoptosis. Bioessays 23, 936-946 (2001).
3. Tzivion, G., Shen, Y. H. & Zhu, J. 14-3-3 proteins; bringing new definitions to scaffolding. Oncogene20, 6331-6338 (2001).
4. Moore, B. W. & Perez V. J. in Physiological and Biochemical Aspects of Nervous Integration (ed. Carlson, F. D.) 343-359 (Prentice-Hall, Englewood Cliffs, New Jersey, 1967).
5. Martin, H. et al. Antibodies against the major brain isoforms of 14-3-3 protein. An antibody specific for the N-acetylated amino-terminus of a protein. FeBS Lett. 331, 296-303 (1993).
6. Aitken, A., Howell, S., Jones, D., Madrazo, J. & Patel, Y. 14-3-3 a and 8 are the phosphorylated forms of raf-activating 14-3-3 β and ζ. In vivo stoichiometric phosphorylation in brain at a Ser-Pro-Glu-Lys motif. J. Biol. Chem. 270, 5706-5709 (1995).
7. Boston, P. F., Jackson, P. & Thompson, R. J. Human 14-3-3 protein: radioimmunoassay, tissue distribution, and cerebrospinal fluid levels in patients with neurological disorders. J. Neurochem. 38, 1475-1482 (1982).
8. Pawson, T. & Scott, J. D. Signaling through scaffold, anchoring, and adaptor proteins. Science 278, 2075-2080 (1997).
9. Baxter, H. C. et al. Specific 14-3-3 isoform detection and immunolocalization in prion diseases. Biochem. Soc. Trans. 30, 387-391 (2002).
10. Fu, H., Subramanian, R. R. & Masters, S. C. 14-3-3 proteins: structure, function, and regulation. Annu. Rev. Pharmacol. Toxicol. 40, 617-647 (2000).
11. Liu, D. et al. Crystal structure of the Zisoform of the 14-3-3 protein. Nature 376, 191-194 (1995).
12. Xiao, B. et al. Structure of a 14-3-3 protein and implications for coordination of multiple signalling pathways. Nature 376, 188-191 (1995).
13. Petosa, C. et al. 14-3-3Z binds a phosphorylated Raf peptide and an unphosphorylated peptide via its conserved amphipathic groove. J. Biol. Chem. 273, 16305-16310 (1998).
14. Wang, H., Zhang, L., Liddington, R. & Fu, H. Mutations in the hydrophobic surface of an amphipathic groove of 14-3-3Z disrupt its interaction with Raf-1 kinase. J. Biol. Chem. 273, 16297-16304 (1998).
15. Wang, W. & Shakes, D. C. Molecular evolution of the 14-3-3 protein family. J. Mol. Evol. 43, 384-398 (1996).
16. Brunet, A. et al. 14-3-3 transits to the nucleus and participates in dynamic nucleocytoplasmatic transport. J. Cell Biol. 156, 817-828 (2002).
17. Aitken, A. Functional specificity in 14-3-3 isoform interactions through dimer formation and phosphorylation. Chromosome location of mammalian isoforms and variants. Plant Mol. Biol. 50, 993-1010 (2002)
18. Muslin, A. J., Tanner, J. W., Allen, P M. & Shaw, A. S. Interaction of 14-3-3 with signaling proteins is mediated by the recognition of phosphoserine. Cell 84, 889-897 (1996).
19. Yaffe, M. B. et al. The structural basis for 14-3-3: phosphopeptide binding specificity. Cell 91, 961-971 (1997).
20. Truong, A. B., Masters, S. C., Yang, H. & Fu, H. Role of the 14-3-3 C-terminal loop in ligand interaction. Proteins 49, 321-325 (2002).
21. Obsil, T., Ghirlando, R., Klein, D. C., Ganguly, S. & Dyda, F. Crystal structure of the 14-3-3Z: serotonin N-acetyltransferase complex: a role for scaffolding in enzyme regulation. Cell 105, 257-267 (2001).
22. Ganguly, S. et al. Role of a pineal cAMP-operated arylalkylamine N-acetyltransferase/14-3-3-binding switch in melatonin synthesis. Proc. Natl Acad. Sci. USA 98, 8083-8088 (2001).
23. Jones, D. H., Ley, S. & Aitken, A. Isoforms of 14-3-3 protein can form homo- and heterodimers in vivo and in vitro: implications for function as adaptor proteins. FEBS Lett. 368, 55-58 (1995).
24. Vincenz, C. & Dixit, V. M. 14-3-3 proteins associate with A20 in an isoform-specific manner and function both as chaperone and adapter molecules. J. Biol. Chem. 271, 20029-20034 (1996).
25. Ferl, R. J., Manak, M. S. & Reyes, M. F. The 14-3-3s. Genome Biol. 3, R3010.1 -3010.7 (2002).
26. Rosenquist, M., Sehnke, P., Ferl, R. J., Sommarin, M. & Larsson, C. Evolution of the 14-3-3 protein family: does the 55. large number of isoforms in multicellular organisms reflect functional specificity? J. Mol. Evol. 51, 446-458 (2000).
27. Aitken, A. 14-3-3 and its possible role in co-ordinating multiple signalling pathways. Trends Cell Biol. 6, 341-347 (1996).
28. Niu, J. et al. RGS3 interacts with 14-3-3 via the N-terminal 57. region distinct from the RGS (regulator of G-protein signalling) domain. Biochem. J. 365, 677-684 (2002).
29. Toska, K. et al. Regulation of tyrosine hydroxylase by stress- activated protein kinases. J. Neurochem. 83, 775-783 (2002).
30. Zhu, P et al. The interaction between ADAM 22 and 14-3-3Z: 58. regulation of cell adhesion and spreading. Biochem. Biophys. Res. Commun. 301, 991-999 (2003).
31. Bunney, T. D., van den Wijngaard, P W. & de Boer, A. H. 14-3-3 protein regulation of proton pumps and ion channels. Plant Mol. Biol. 50, 1041-1051 (2002).
32. Fantl, W. J. et al. Activation of Raf-1 by 14-3-3 proteins. Nature 371, 612-614 (1994).
33. Irie, K. et al. Stimulatory effects of yeast and mammalian 14-3-3 proteins on the Raf protein kinase. Science 265, 1716-1719 (1994).
34. Morrison, D. K. & Cutler, R. E. The complexity of Raf-1 regulation. Curr. Opin. Cell Biol. 9, 174-179 (1997).
35. Williams, N. G. & Roberts, T. M. Signal transduction pathways involving the Raf proto-oncogene. Cancer Metastasis Rev. 13, 105-116 (1994).
36. Yip-Schneider, M. T. et al. Regulation of the Raf-1 kinase domain by phosphorylation and 14-3-3 association. Biochem. J. 351, 151-159 (2000).
37. Braselmann, S. & McCormick, F. Bcr and Raf form a complex in vivo via 14-3-3 proteins. EMBO J. 14, 4839-4848 (1995).
38. Yamamori, B. et al. Purification of a Ras-dependent mitogen-activated protein kinase kinase kinase from bovine 65. brain cytosol and its identification as a complex of B-Raf and 14-3-3 proteins. J. Biol. Chem. 270, 11723-11726 (1995).
39. Xing, H., Kornfeld, K. & Muslin, A. J. The protein kinase KSR interacts with 14-3-3 protein and Raf. Curr. Biol. 7, 294-300 66. (1997).
40. Kiryu, S., Morita, N., Ohno, K., Maeno, H. & Kiyama, H. Regulation of mRNA expression involved in Ras and PKA signal pathways during rat hypoglossal nerve regeneration. 67. Brain Res. Mol. Brain Res. 29, 147-156 (1995).
41. Dhillon, A. S. et al. A Raf-1 mutant that dissociates MEK/extracellular signal-regulated kinase activation from malignant transformation and differentiation but not proliferation. Mol. Cell. Biol. 23, 1983-1993 (2003).
42. Dhaka, A. et al. The RAS effector RIN1 modulates the formation of aversive memories. J. Neurosci. 23, 748-757 (2003).
43. Namikawa, K., Su, Q., Kiryu-Seo, S. & Kiyama, H. Enhanced expression of 14-3-3 family members in injured motoneurons. Brain Res. Mol. Brain Res. 55, 315-320 (1998).
44. Cavet, M. E., Lehoux, S. & Berk, B. C. 14-3-3p is a p90 ribosomal S6 kinase isoform 1 (RSK1) binding protein that 70. negatively regulates RSK kinase activity. J. Biol. Chem. 16, 18376-18386 (2003).
45. Goossens, J. et al. Expression of protein kinase C inhibitor 71. blocks cerebellar long-term depression without affecting Purkinje cell excitability in alert mice. J. Neurosci. 21, 5813-5823 (2001).
46. Ling, D. S. et al. Protein kinase MZ is necessary and sufficient for LTP maintenance. Nature Neurosci. 5, 295-296 (2002).
47. Colombo, P J., Wetsel, W. C. & Gallagher, M. Spatial memory is related to hippocampal subcellular concentrations of calcium-dependent protein kinase C isoforms in young and aged rats. Proc. Natl Acad. Sci. USA 74. 94, 14195-14199 (1997).
48. Routtenberg, A., Cantallops, I., Zaffuto, S., Serrano, P & Namgung, U. Enhanced learning after genetic overexpression of a brain growth protein. Proc. Natl Acad. Sci. USA 97, 7657-7662 (2000).
49. Dai, J. G. & Murakami K. Constitutively and autonomously 76. active protein kinase C associated with 14-3-3Z in the rodent brain. J. Neurochem. 84, 23-34 (2003).
50. Chen, D.-H. et al. Missense mutations in the regulatory domain of PKCy: a new mechanism for dominant nonepisodic cerebellar ataxia. Am. J. Hum. Genet. 72, 839-949 (2003).
51. Zha, J., Harada, H., Yang, E., Jockel, J. & Korsmeyer, S. J. Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-Xl. Cell 79. 87, 619-628 (1996).
52. Nomura, M. et al. 14-3-3 Interacts directly with and negatively regulates pro-apoptotic Bax. J. Biol. Chem. 278, 2058-2065 (2003).
53. Zhang, L., Chen, J. & Fu, H. Suppression of apoptosis signal-regulating kinase 1-induced cell death by 14-3-3 proteins. Proc. Natl Acad. Sci. USA 96, 8511-8515 (1999).
54. Brunet, A. et al. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 96, 857-868 (1999).
55. Xing, H., Zhang, S., Weinheimer, C., Kovacs, A. & Muslin, A. J. 14-3-3 proteins block apoptosis and differentially regulate MAPK cascades. EMBO J. 19, 349-358 (2000).
56. Basu, S., Totty, N. F., Iwin, M. S., Sudol, M. & Downward, J. Akt phophorylates the Yes-associated protein, YAP, to induce interaction with 14-3-3 and attenuation of p73- mediated apoptosis. Mol. Cell 11, 11-23 (2003).
57. Muslin, A. J. & Xing, H. 14-3-3 proteins: regulation of subcellular localization by molecular interference. Cell Signal. 12, 703-709 (2000).
58. Seimiya, H. et al. Involvement of 14-3-3 proteins in nuclear localization of telomerase. EMBO J. 19, 2652-2661 (2000).
59. Zhang, P., Chan, S. L., Fu, W., Mendoza, M. & Mattson, M. P. TERT suppresses apoptotis at a premitochondrial step by a mechanism requiring reverse transcriptase activity and 14-3-3 protein binding ability. FASEB J. 17, 767-769 (2003).
60. Kimura, M. T. et al. 14-3-3 is involved in p75 neurtorphin receptor-mediated signal transduction. J. Biol. Chem. 276, 17291-17300 (2001).
61. Marra, M. et al. The 30-kilodalton protein present in purified fusicoccin receptor preparations is a 14-3-3-like protein. Plant Physiol. 106, 1497-501 (1994).
62. Booij, P. P., Roberts, M. R., Vogelzang, S. A., Kraayenhof, R. & De Boer, A. H. 14-3-3 proteins double the number of outward-rectifying K+ channels available for activation in tomato cells Plant J. 20, 673-683 (1999).
63. -channel by 14-3-3e Biochem. Biophys. Res. Commun. 270, 581-587 (2000).
64. Zhou, Y. et al. A dynamically regulated 14-3-3, Slob, and Slowpoke potassium channel complex in Drosophila presynaptic nerve terminals. Neuron 22, 809-818 (1999)
65. Sugita, W., Karoulias, N., Aitken, A. & Ashley, R. H. Chloride intracellular channel protein (CLIC4) (p64H1) binds directly to braindynamin I in a complex containing actin, tubulin and 14-3-3 isoforms. Biochem. J. 359, 55-64 (2001).
66. Kagan, A., Melman, Y. F., Krumerman, A. & McDonald, T. V. 14-3-3 amplifies and prolongs adrenergic stimulation of HERG K+ channel activity. EMBO J. 21, 1889-1898 (2002).
67. Rajan, S. et al. Interaction with 14-3-3 proteins promotes functional expression of the potassium channels TASK-1 and TASK-3. J. Physiol. (Lond.) 545, 13-26 (2002).
68. Goldstein, S. A. N. et al. Potassium leak channels and the KCNK family of two-P-domain subunits. Nature Rev. Neurosci. 2, 175-184 (2001).
69. Lopez, C. J. A new TASK for 14-3-3 proteins. Nature Rev. Neurosci. 3, 915 (2002).
70. Kim, Y., Bang, H. & Kim, D. TASK-3, a new member of the tandem pore K+ channel family. J. Biol. Chem. 275, 9340-9347 (2000).
71. Rajan, S. et al. TASK-3, a novel tandem pore domain acid- sensitive K+ channel — an extracellular histidine as pH sensor. J. Biol. Chem. 275, 16650-16657 (2000).
72. Skoulakis, E. M. & Davis, R. L. 14-3-3 proteins in neuronal development and function. Mol. Neurobiol. 16, 269-284 (1998)
73. Peyril, A., Weitzdoerfer, R., Gulesserian, T., Fountoulakis, M. & Lubec G. Aberrant expression of signaling-related proteins 14-3-3y and RACK1 in fetal Down syndrome brain (trisomy 21). Electrophoresis 23, 152-157 (2002).
74. Kato, M. & Dobyns, W. B. Lissencephaly and the molecular basis of neuronal migration. Hum. Mol. Genet. 12, R89-R96 (2003).
75. Toyo-oka, K. et al. 14-3-3s is important for neuronal migration by binding to NUDEL: a molecular explanation for Miller-Dieker syndrome. Nature Genet. 34, 274-285 (2003)
76. Will, R. G. Epidemiology of Creutzfeld-Jakob disease. Br. Med. Bull. 49, 960-970 (1993).
77. Kretzschmar, H. A., Ironside, J. W., DeArmond, S. J. & Tateishi, J. Diagnostic criteria for sporadic Creutzfeldt-Jakob disease. Arch. Neurol. 53, 913-920 (1996)
78. Harrington, M. G., Merril, C. R., Asher, D. M. & Gajdusek, D. C. Abnormal proteins in the cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. N. Engl. J. Med. 315, 279-283 (1986).
79. Hsich, G., Kenney, K., Gibbs, C. J., Lee, K. H. & Harrington, M. G. The 14-3-3 brain protein in cerebrospinal fluid as a marker for transmissible spongiform encephalopathies. N. Engl. J. Med. 335, 24-30 (1996).
80. Zerr, I. et al. Detection of 14-3-3 protein in the cerebrospinal fluid supports the diagnosis of Creutzfeldt-Jakob disease. Ann. Neurol. 43, 32-40 (1998).
81. Beaudry, P. et al. 14-3-3 protein, neuron-specific enolase, and S-100 protein in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. Dement. Geriatr. Cogn. Disord. 10, 40-46 (1999).
82. Brandel, J. P., Delasnerie-Laupretre, N., Laplanche, J. L., Hauw, J. J. & Alperovitch, A. Diagnosis of Creutzfeldt-Jakob disease: effect of clinical criteria on incidence estimates. Neurology 54, 1095-1099 (2000).
83. Lemstra, A. W. et al. 14-3-3 testing in diagnosing Creutzfeldt-Jakob disease: a prospective study in 112 patients. Neurology 55, 514-516 (2000).
84. World Health Organization. Giobaisurveillance, diagnosis and therapy ofhuman transmissible spongiform encephalopathies: Report ofa WHO consuitaton WHO/EMC/ZDI/98/9 (World Health Organization, Geneva, 1998).
85. Burkhard, P. R., Sanchez, J. C., Landis, T. & Hochstrasser, D. F. CSF detection of the 14-3-3 protein in unselected patients with dementia. Neurology 56, 1528-1533 (2001).
86. Will, R. G. et al. Diagnosis of new variant of Creutzfeldt- Jakob disease. Ann. Neurol. 47, 575-582 (2000).
87. Green, A. J. et al. Use of 14-3-3 and other brain-specific proteins in CSF in the diagnosis of variant Creutzfeldt-Jakob disease. J. Neurol. Neurosurg. Psychiatry 70, 744-748 (2001).
88. Green, A. J., Ramljak, S., Muller, W. E., Knight, R. S. & Schroder H. C. 14-3-3 in the cerebrospinal fluid of patients with variant and sporadic Creutzfeldt-Jakob disease measured using capture assay able to detect low levels of 14-3-3 protein. Neurosci. Lett. 324, 57-60 (2002).
89. Collins, S. et al. Creutzfeld-Jakob diease: diagnostic utility of 14-3-3 immunodetection in cerbrospinal fluid. J. Clin. Neurosci. 7, 203-208 (2000).
90. Haik, S. et al. Dementia with Lewy bodies in a neuropathologic series of suspected Creutzfeldt-Jakob disease. Neurology 55, 1401-1404 (2000).
91. Kenney, K. et al. An enzyme-linked immunosorbent assay to quantify 14-3-3 proteins in the cerebrospinal fluid of suspected Creutzfeldt-Jakob disease patients. Ann. Neurol. 48, 395-398 (2000).
92. Wiltfang, J. et al. Isoform pattern of 14-3-3 proteins in the cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. J. Neurochem. 73, 2485-2490 (1999).
93. Baxter, H. C., Liu, W. G., Forster, J. L., Aitken, A. & Fraser, J. R. Immunolocalisation of 14-3-3 isoforms in normal and scrapie- infected murine brain. Neuroscience 109, 5-14 (2002).
94. Richard, M. et al. Immunohistochemical localization of 14.3.3Z protein in amyloid plaques in human spongiform encephalopathies. Acta Neuropathol. 105, 296-302 (2003)
95. Pietromonaco, S. F, Seluja, G. A., Aitken, A. & Elias, L. Association of 14-3-3 proteins with centrosomes. Biood Cells Mol. Dis. 22, 225-237 (1996).
96. Martin, H., Rostas, J., Patel, Y. & Aitken, A. Subcellular localisation of 14-3-3 isoforms in rat brain using specific antibodies. J. Neurochem. 63, 2259-2265 (1994).
97. Jones, D. H. et al. Expression and structural analysis of 14-3-3 proteins. J. Mol. Biol. 245, 375-384 (1995).
98. Moya, K. L. et al. Immunolocalization of the cellular prion protein in normal brain. Microsc. Res. Tech. 50, 58-65 (2000).
99. Goedert, M. Tau protein and the neurofibrillary pathology of Alzheimer's disease. Trends Neurosci. 16, 460-465 (1993).
100. Alonso, A. C., Zaidi, T., Grundke-Iqbal, I. & Iqbal, K. Role of abnormally phosphorylated tau in the breakdown of microtubules in Alzheimer disease. Proc. Natl Acad. Sci. USA 91, 5562-5566 (1994).
101. Hirokawa, N. Microtubule organization and dynamics dependent on microtubule-associated proteins. Curr. Opin. Cell Biol. 6, 74-81 (1994).
102. Lee, V. M. Disruption of the cytoskeleton in Alzheimer's disease. Curr. Opin. Neurobiol. 5, 663-668 (1995).
103. Lee, V. M., Goedert, M. & Trojanowski, J. Q. Neurodegenerative tauopathies. Annu. Rev. Neurosci. 24, 1121-1159 (2001).
104. Wang, J. Z., Gong, C. X., Zaidi, T., Grundke-Iqbal, I. & Iqbal, K. Dephosphorylation of Alzheimer paired helical filaments by protein phosphatase-2A and -2B. J. Biol. Chem. 270, 4854-4860 (1995).
105. Hashiguchi, M., Sobue, K. & Paudel, H. K. 14-3-3Z is an effector of tau protein phosphorylation. J. Biol. Chem. 275, 25247-25254 (2000).
106. Fountoulakis, M., Cairns, N. & Lubec, G. Increased levels of 14-3-3yand e proteins in brain of patients with Alzheimer's disease and Down syndrome. J. Neural. Transm. Suppi. 57, 323-335 (1999).
107. Layfield, R. et al. Neurofibrillary tangles of Alzheimer's disease brains contain 14-3-3 proteins. Neurosci. Lett. 209, 57-60 (1996).
108. Paudel, H. K. Phosphorylation by neuronal cdc2-like protein kinase promotes dimerization of Tau protein in vitro. J. Biol. Chem. 272, 28328-28334 (1997).
109. Sun, W. et al. Glycogen synthase kinase-3P is complexed with tau protein in brain microtubules. J. Biol. Chem. 277, 11933-11940 (2002).
110. Agarwal-Mawal, A. et al. 14-3-3 connects glycogen synthase kinase-3P to tau within a brain microtubule- associated tau phosphorylation complex. J. Biol. Chem. 11, 12722-12728 (2003).
111. Luo, Z. et al. Oligomerization activates c-Raf-1 through a Ras-dependent mechanism. Nature 383, 181-185 (1996).
112. Dent, P, Jelinek, T., Morrison, D. K., Weber, M. J. & Sturgill, T. W. Reversal of Raf-1 activation by purified and membrane-associated protein phosphatases. Science 268, 1902-1906 (1995).
113. Tschampa, H. J. et al. Patients with Alzheimer's disease and dementia with Lewy bodies mistaken for Creutzfeldt-Jakob disease. J. Neuroi. Neurosurg. Psychiatry 71, 33-39 (2001).
114. Hughes, A. J., Ben-Shlomo, Y., Daniel, S. E. & Lees, A. J. What features improve the accuracy of clinical diagnosis in Parkinson's disease: a clinicopathologic study. Neurology 42, 1142-1146 (1992).
115. Jellinger, K. A. Pathology of Parkinson's disease. Changes other than the nigrostriatal pathway. Mol. Chem. Neuropathol. 14, 153-197 (1991).
116. Braak, H. et al. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol. Aging 24, 197-211 (2003).
117. McKeith I. G. et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neuroiogy. 47, 1113-1124 (1996).
118. Kawamoto, Y. et al. 14-3-3 proteins in Lewy bodies in Parkinson disease and diffuse Lewy body disease brains. J. Neuropathol. Exp. Neurol 61, 245-253 (2002).
119. Ubl, A. et al. 14-3-3 protein is a component of Lewy bodies in Parkinson's disease-mutation analysis and association studies of 14-3-3n. Brain Res. Mol. Brain Res. 108, 33-39 (2002).
120. Berg, D., Riess, O. & Bornemann, A. Specification of 14-3-3 proteins in Lewy bodies. Ann. Neuroi. 53, 135 (2003).
121. Ostrerova, N. et al. a-Synuclein shares physical and functional homology with 14-3-3 proteins. J. Neurosci. 19, 5782-5791 (1999).
122. Ichimura, T. et al. Molecular cloning fo c-DNA coding for brain-specific 14-3-3 protein, a protein kinase-dependent activator of tyrosine and tryptophan hydroxylases. Proc. Natl Acad. Sci. USA 85, 7084-7088 (1988).
123. 2+-, calmodulin-dependent protein kinase. Purification and characterization. J. Biol. Chem. 256, 5404-5409 (1981).
124. 2+-, calmodulin- dependent protein kinase II. FEBS Lett. 219, 79-82 (1987).
125. Kleppe, R., Toska, K. & Haavik, J. Interaction of phosphorylated tyrosine hydroxylase with 14-3-3 proteins: evidence for a phosphoserine 40-dependent association. J. Neurochem. 77, 1097-1107 (2001).
126. Perez, R. G. et al. A role for a-synuclein in the regulation of dopamine biosynthesis. J. Neurosci. 22, 3090-3099 (2002).
127. Welch, K. & Yuan, J. Releasing the nerve cell killers. Nature Med. 8, 564-565 (2002).
128. Xu, J. et al. Dopamine-dependent neurotoxicity of a-synuclein: a mechanism for selective neurodegeneration in Parkinson disease. Nature Med. 8, 600-606 (2002).
129. Kruger, R. et al. Ala30Pro mutation in the gene encoding a-synuclein in Parkinson's disease. Nature Genet. 18, 106-108 (1998).
130. Polymeropoulos, M. H., et al. et al. Mutation in the a-synuclein gene identified in families with Parkinson's disease. Science. 276, 2045-2047 (1997).
131. Holzmann, C. et al. Polymorphisms of the a-synuclein promoter: expression analyses and association studies in Parkinson's disease. J. Neurai Transm. 110, 67-76 (2003).
132. Kruger, R. et al. Increased susceptibility to sporadic Parkinson's disease by a certain combined a-synuclein/apolipoprotein E genotype. Ann. Neurol. 45, 611-617 (1999).
133. Paulson, H. L. et al. Intranuclear inclusions of expanded polyglutamine protein in spinocerebellar ataxia type 3. Neuron 19, 333-344 (1997).
134. Skinner, P. J. et al. Ataxin-1 with an expanded glutamine tract alters nuclear matrix-associated structures. Nature 389, 971-974 (1997).
135. Holmberg, M. et al. Spinocerebellar ataxia type 7 (SCA7): a neurodegenerative disorder with neuronal intranuclear inclusions. Hum. Moi. Genet. 7, 913-918 (1998).
136. Chen, H.-K. et al. Interaction of Akt-phophorylated ataxin-1 with 14-3-3 mediates neurodegeneration in spinocerebellar ataxia type 1. Cell 113, 457-468 (2003).
137. McCampbell, A. et al. CREB-binding protein sequestration by expanded polyglutamine. Hum. Moi. Genet. 9, 2197-2202 (2000).
138. Shimohata, T. et al. Expanded polyglutamine stretches interact with TAFII130, interfering with CREB-dependent transcription. Nature Genet. 26, 29-36 (2000).
139. Grozinger, C. M. & Schreiber, S. L. Regulation of histone deacetylase 4 and 5 and transcriptional activity by 14-3-3 dependent cellular localization. Proc. Natl Acad. Sci. USA 97, 7835-7840 (2000).
140. Dunah, A. W. et al. Sp1 and TAFII130 transcriptional activity disrupted in early Huntington's disease. Science 296, 2238-2243 (2002).
141. Steffan, J. S. et al. Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophlla. Nature 413, 739-743 (2001).
142. Grove, V. E. Jr, Quintanilla, J. & DeVaney, G. T. Improvement of Huntington's disease with olanzapine and valproate. New Engi. J. Med. 343, 973-974 (2000).
143. Malaspina, A., Kaushik, N. & de Belleroche J. A. 14-3-3 mRNA is up-regulated in amyotrophic lateral sclerosis spinal cord. J. Neurochem. 75, 2511-2520 (2000)
144. Wakabayashi, H. et al. Increased concentrations of 14-3-3 e, y and Z isoforms in cerebrospinal fluid of AIDS patients with neuronal destruction. Clin. Chim. Acta. 312, 97-105 (2001).
145. Miller, R. F., Green, A. J., Giovannoni, G. & Thompson, E. J. Detection of 14-3-3 brain protein in cerebrospinal fluid of HIV infected patients. Sex Transm. Infect. 76, 408 (2000).
146. Zerr, I. et al. Current clinical diagnosis in Creutzfeldt-Jakob disease: identification of uncommon variants. Ann. Neurol. 48, 323-329 (2000).
147. Rosenmann, H. et al. Detection of 14-3-3 protein in the CSF of genetic Creutzfeldt-Jakob disease. Neurology 49, 593-595 (1997).
148. Satoh, J., Kurohara, K., Yukitake, M. & Kuroda, Y. The 14-3-3 protein detectable in the cerebrospinal fluid of patients with prion-unrelated neurological diseases is expressed constitutively in neurons and glial cells in culture. Eur. Neurol. 41, 216-225 (1999).
149. Saiz, A., Marin, C., Tolosa, E. & Graus, F. Diagnostic usefulness of the determination of protein 14-3-3 in cerebrospinal fluid in Creutzfeldt-Jakob disease. Neurologia 13, 324-328 (1998).
150. Will, R. G. et al. Cerbrospinal fluid test for new-variant Creutzfeldt-Jakob disease. Lancet 348, 955 (1996).
151. Saiz, A. et al. Detection of 14-3-3 brain protein in the cerebrospinal fluid of patients with paraneoplastic neurological disorders. Ann. Neurol. 46, 774-777 (1999).
152. Hernandez Echebarria, L. E. et al. Detection of 14-3-3 protein in the CSF of a patient with Hashimoto's encephalopathy. Neurology 54, 1539-1540 (2000).
153. Irani, D. N. & Kerr, D. A. 14-3-3 protein in the cerebrospinal fluid of patients with acute transverse myelitis. Lancet 355, 901 (2000).
154. Thompson, J. D., Gibson, T. J., Plewniak, F., Jeanmougin, F. & Higgins, D. G. The CLUSTAL_X windows interface: flexible strategies for multiple sequence alignment aided by quality analysis tools. Nucieic Acids Res. 25, 4876-4882 (1997).
155. Kimura, M. Evolutionary rate at the molecular level. Nature 217, 624-626 (1968).
156. Page, R. D. TreeView: an application to display phylogenetic trees on personal computers. Comput. Appl. Biosci. 12, 357-358 (1996).
157. Perriere, G. & Gouy, M. WWW-query: an on-line retrieval system for biological sequence banks. Biochimie 78, 364-369 (1996).